IPO UPDATE: Intrexon rises 81% in 2 days; also Sophiris, Ruthigen, Acceleron, Iroko
This article was originally published in Scrip
Intrexon chairman and CEO Randal Kirk took a page from Quintiles executive chairman Dennis Gillings's playbook and cashed in on his investments in the synthetic biology company with an initial public offering that increased the majority shareholder's net worth by another $1 billion.
You may also be interested in...
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
Public Company Edition: Long-struggling Regulus is laying off employees and pausing its two clinical programs. Also, Ironwood is shuffling staff ahead of splitting into two companies and will cut 40 jobs in the process. And among several loan agreements and note sales, Tesaro borrows another $200m.
VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.